Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction
NCT ID: NCT01768910
Last Updated: 2019-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
91 participants
INTERVENTIONAL
2011-12-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional Changes in the Brain After Tibial Nerve Stimulation: a Pilot Study
NCT03908047
Study of Electroencephalogram (EEG) Measurement During Different Stimulations of the Lower Urinary Tract
NCT01389921
Brain Network Activation in Patients With Movement Disorders
NCT03269201
The Supraspinal Control of Lower Urinary Tract Function in Patients with Orthotopic Sigmoid Neobladder.
NCT05558111
Physiologic Studies of Spasticity
NCT00014976
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following subject groups will be recruited: 1) healthy controls (n=22), Non-neurogenic overactive bladder (NNOAB) patients (n=20), multiple sclerosis (MS) patients with OAB (n=15), MS patients without OAB (n=15), spinal cord injury (SCI) patients with neurogenic detrusor overactivity (n=24).
After inclusion, all subjects and patients will undergo one to two functional magnetic resonance imaging (fMRI) sessions. NNOAB patients might undergo an additional fMRI session after receiving overactive bladder (OAB) treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A). Spinal cord injury (SCI) patients with neurogenic detrusor overactivity will undergo an additional fMRI session 5-7 weeks after intradetrusor injections of botulinum toxin type A.
High-resolution anatomical images and functional blood-oxygen-level-dependent (BOLD)-signal sensitive images will be acquired. In addition to the fMRI, diffusion tensor imaging (DTI) sequences will be recorded after the anatomical scans to provide information about the structural supraspinal connectivity.
Study endpoints are changes of the BOLD signal in regard to location and intensity, structural and functional connectivity (FC) between previously described supraspinal centers involved in LUT control, and statistical differences of changes in BOLD signals, structural and functional connectivity between patients and healthy controls.
All acquired fMRI data will be transferred to an off-line workstation running BrainVoyager QX or Statistical Parametric Mapping (SPM) Version 8. The functional data will be pre-processed for motion correction, spatial smoothing, linear trend removal, and temporal high-pass filtering. With both programs statistical analysis and graphical presentation of the results can be performed.
The DTI records will be evaluated with SPM8, BrainVoyager QX or other programs like Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL) and DTI-Studio. To estimate FC we will use SPM8 or the brain connectivity toolbox. Both softwares allow the estimation of rest- and task-related connectivity on single subject and group level with corrected statistical threshold.
Overall, 96 subjects for the main study are estimated to be sufficient to demonstrate significant differences between groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy controls
Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
fMRI
2 measurements using functional magnetic resonance imaging in a 3T scanner
bladder filling
Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
bladder cooling
Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
MS with OAB
Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
fMRI
2 measurements using functional magnetic resonance imaging in a 3T scanner
bladder filling
Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
bladder cooling
Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
MS without OAB
Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
fMRI
2 measurements using functional magnetic resonance imaging in a 3T scanner
bladder filling
Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
bladder cooling
Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
NNOAB
Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
fMRI
2 measurements using functional magnetic resonance imaging in a 3T scanner
bladder filling
Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
bladder cooling
Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
additional post-treatment fMRI scan
Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
SCI with neurogenic detrusor overactivity
Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
fMRI
2 measurements using functional magnetic resonance imaging in a 3T scanner
bladder filling
Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
bladder cooling
Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
additional post-treatment fMRI scan
Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fMRI
2 measurements using functional magnetic resonance imaging in a 3T scanner
bladder filling
Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
bladder cooling
Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
additional post-treatment fMRI scan
Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right handed
* MR suitability
* Written informed consent
* unimpaired LUT function
MS patients with OAB
* Right handed
* MR suitability
* Written informed consent
* diagnosis of MS according to the McDonald criteria
* Expanded Disability Status Scale (EDSS) ≤ 6
* OAB symptoms since \> 6 months
* ≥ 3 episodes of urinary urgency
* frequency \> 8/24h
* with or without detrusor overactivity
MS patients without OAB
* Right handed
* MR suitability
* Written informed consent
* diagnosis of MS according to the McDonald criteria
* Expanded Disability Status Scale (EDSS) ≤ 6
Patients with NNOAB
* Right handed
* MR suitability
* Written informed consent
* idiopathic OAB symptoms since \> 6 months
* ≥ 3 episodes of urinary urgency
* frequency \> 8/24h
* refractory to antimuscarinic treatment for ≥ 1 month
* indication for intradetrusor injections of Botulinumtoxin Type A
* willingness and ability to perform self-catheterization
SCI patients with neurogenic detrusor overactivity
* Right handed
* MR suitability
* Written informed consent
* neurogenic detrusor overactivity due to SCI
* indication for intradetrusor injections of botulinum toxin type A
Exclusion Criteria
* impaired LUT function
* pregnancy or breast feeding
* no informed consent
* any craniocerebral injury or surgery
* any permanent ferromagnetic implant
* any previous surgery of the LUT or genitalia
* any anatomical anomaly of the LUT or genitalia
* any LUT malignancy
* postvoid residual urine volume (PVR) \> 150ml
* current urinary tract infection
* any LUT symptoms
* ≥ 3 episodes of urinary urgency
* frequency \> 8/24h
MS patients with OAB
* pregnancy or breast feeding
* any permanent ferromagnetic implant
* any neurological or psychological disease despite MS
* any craniocerebral injury or surgery
* any previous surgery of the LUT or genitalia
* any anatomical anomaly or malignancy of the LUT or genitalia
* any metabolic disease
* PVR \> 150ml
* any concomitant treatment for the LUT (e.g. neuromodulation)
* Stress urinary incontinence
* any condition other than MS that might explain OAB symptoms
* current urinary tract infection
* indwelling catheters or the necessity to perform self-catheterization
MS patients without OAB
* pregnancy or breast feeding
* any permanent ferromagnetic implant
* any neurological or psychological disease despite MS
* any craniocerebral injury or surgery
* any previous surgery of the LUT or genitalia
* any anatomical anomaly or malignancy of the LUT or genitalia
* any metabolic disease
* PVR \> 150ml
* any concomitant treatment for the LUT (e.g. neuromodulation)
* Stress urinary incontinence
* any LUT symptoms
* ≥ 3 episodes of urinary urgency
* frequency \> 8/24h
* indwelling catheters or the necessity to perform self-catheterization
* detrusor overactivity
* current urinary tract infection
Patients with NNOAB
* pregnancy or planned within next 8 months, breast feeding
* any permanent ferromagnetic implant
* any neurological, psychological, metabolic or cardiovascular disease
* any craniocerebral injury or surgery
* any previous surgery of the LUT or genitalia within the last year or that is related to the OAB symptoms
* any anatomical anomaly or malignancy of the LUT or genitalia
* PVR \> 150ml
* Stress urinary incontinence
* indwelling catheters or the necessity to perform self-catheterization
* any concomitant treatment for the LUT (e.g. neuromodulation)
* current urinary tract infection
SCI patients with neurogenic detrusor overactivity
* pregnancy or breast feeding
* any permanent ferromagnetic implant
* any neurological or psychological disease despite SCI
* any craniocerebral injury or surgery
* any previous surgery of LUT of genitalia
* any anatomical anomaly or malignancy of the LUT or genitalia
* any metabolic disease
* any concomitant treatment for the LUT (e.g. neuromodulation)
* current urinary tract infection
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swiss National Science Foundation
OTHER
Balgrist University Hospital
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrich Mehnert, MD
Role: PRINCIPAL_INVESTIGATOR
Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland
Thomas M Kessler, MD
Role: PRINCIPAL_INVESTIGATOR
Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland
Spyros Kollias, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Neuroradiology, University Hospital Zurich, Sternwartstrasse 6, 8091 Zurich, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital
Zurich, , Switzerland
University Hospital Zürich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Walter M, Michels L, Kollias S, van Kerrebroeck PE, Kessler TM, Mehnert U. Protocol for a prospective neuroimaging study investigating the supraspinal control of lower urinary tract function in healthy controls and patients with non-neurogenic lower urinary tract symptoms. BMJ Open. 2014 May 21;4(5):e004357. doi: 10.1136/bmjopen-2013-004357.
Leitner L, Walter M, Freund P, Mehnert U, Michels L, Kollias S, Kessler TM. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity. BMC Urol. 2014 Aug 18;14:68. doi: 10.1186/1471-2490-14-68.
Leitner L, Walter M, Jarrahi B, Wanek J, Diefenbacher J, Michels L, Liechti MD, Kollias SS, Kessler TM, Mehnert U. A novel infusion-drainage device to assess lower urinary tract function in neuro-imaging. BJU Int. 2017 Feb;119(2):305-316. doi: 10.1111/bju.13655. Epub 2016 Oct 20.
Walter M, Leitner L, Michels L, Liechti MD, Freund P, Kessler TM, Kollias S, Mehnert U. Reliability of supraspinal correlates to lower urinary tract stimulation in healthy participants - A fMRI study. Neuroimage. 2019 May 1;191:481-492. doi: 10.1016/j.neuroimage.2019.02.031. Epub 2019 Feb 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEK-ZH-2011-0346/PB_2016-00872
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.